Association of Interleukin-6 rs1800795 and Interleukin-1A rs1800587 Genetic Variants and Their Serum Levels with the Risk of Endometrial Carcinoma in Egyptian Women
Keywords:
Endometrial carcinoma, IL-6, IL-1A, rs1800795, rs1800587Abstract
BACKGROUND: Endometrial carcinoma (EC) is the most common gynecological malignancy in women globally. Interleukin-6 (IL-6) and interleukin-1A (IL-1A) are pro-inflammatory cytokines that play a role in immune response against EC. Several genetic variations, such as polymorphism, may alter interleukins expression and influence the risk of EC susceptibility.
AIM: The objective of this study is to investigate the association of IL-6 (rs1800795) and IL-1A (rs1800587) polymorphisms and their serum levels with the development of EC versus healthy controls, as well EC prognosis by distribution of these polymorphisms in stages, grades, and histotypes of EC patients in Egyptian women.
METHODS: One hundred EC patients and 100 cancer-free controls were recruited in this case–control study. Polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) was used for genotyping of IL-6 rs1800795 and IL-1A rs1800587 polymorphisms in both groups. ELISA was performed to measure the levels of IL-6 and IL-1A in all participants.
RESULTS: The proportions of C allele, homozygous CC genotype, and heterozygous GC genotype of IL-6 rs1800795 polymorphism were significantly elevated in EC patients when compared with the control individuals. IL-6 rs1800795 CC genotype was significantly greater in the advanced stage than in the early stage of EC. However, IL-1A rs1800587 polymorphism’s T allele and genotypes (TT and CT) were not associated with EC patients versus healthy controls. Furthermore, EC patients exhibited significantly higher serum levels of IL-6 and IL-1A than the healthy controls. The genotypes’ distribution of IL-6 rs1800795 and IL-1A rs1800795 was not significantly associated with their serum levels in EC patients and controls.
CONCLUSIONS: IL6 rs1800795 CC genotype was associated with EC, particularly in the advanced stage, and this suggests that this genotype represents a prognostic biomarker for EC. In addition, both IL-6 and IL-1A serum levels were significantly elevated in EC patients when compared with healthy individuals, suggesting a potential value in differential diagnosis of the disease.Downloads
Metrics
References
Brüggmann D, Ouassou K, Klingelhöfer D, Bohlmann MK, Jaque J, Groneberg DA. Endometrial cancer: Mapping the global landscape of research. J Transl Med. 2020;18(1):386. https://doi.org/10.1186/s12967-020-02554-y PMid:33046107
Fatima I, Barman S, Rai R, Thiel KW, Chandra V. Targeting Wnt signaling in endometrial cancer. Cancers (Basel). 2021;13(10):2351. https://doi.org/10.3390/cancers13102351 PMid:34068065
Yang Y, Wu J, Zhou H, Liu W, Wang J, Zhang Q. STAT1-induced upregulation of lncRNA LINC01123 predicts poor prognosis and promotes the progression of endometrial cancer through miR- 516b/KIF4A. Cell Cycle. 2020;19(12):1502-16. https://doi.org/10.1080/15384101.2020.1757936 PMid:32401659
Zeng X, Li J, Kang LN, Xi MR, Liao GD. Potential clinical value of interleukin-31 and interleukin-33 with their receptors expression as diagnostic and predictive factors in endometrial cancer: A case-control study. Int J Clin Exp Pathol. 2020;13(6):1324-32. PMid:32661468
Wang C, Tran DA, Fu MZ, Chen W, Fu SW, Li X. Estrogen receptor, progesterone receptor, and HER2 receptor markers in endometrial cancer. J Cancer. 2020;11(7):1693-701. https://doi.org/10.7150/jca.41943 PMid:32194781
Luna C, Balcacer P, Castillo P, Huang M, Alessandrino F. Endometrial cancer from early to advanced-stage disease: An update for radiologists. Abdom Radiol (NY). 2021;46(11):5325-36. https://doi.org/10.1007/s00261-021-03220-7 PMid:34297164
Browning L, Patel M, Horvath EB, Tawara K, Jorcyk CL. IL-6 and ovarian cancer: Inflammatory cytokines in promotion of metastasis. Cancer Manag Res. 2018;10:6685-93. https://doi.org/10.2147/CMAR.S179189 PMid:30584363
Xu B, Niu XB, Wang ZD, Cheng W, Tong N, Mi YY, et al. IL-6-174G > C polymorphism and cancer risk: A meta-analysis involving 29, 377 cases and 37, 739 controls. Mol Biol Rep. 2011;38(4):2589-96. https://doi.org/10.1007/s11033-010-0399-1 PMid:21104146
Magalhães JF, Cortinhas AJ, Albuquerque CM, Baptista CS, Ribeiro R, Viegas C, et al. Interleukin-6 gene-174G>C and- 636G>C promoter polymorphisms and prostate cancer risk. Mol Biol Rep. 2013;40(1):449-55. https://doi.org/10.1007/s11033-012-2079-9 PMid:23073774
Wang HY, Zhang JJ, Zheng XY, Liu JH, Li YW. Association between IL-6 Gene (−174 &-572 G/C) polymorphisms and endometrial adenocarcinoma risk. Pathol Oncol Res. 2016;22(4):825-9. https://doi.org/10.1007/s12253-016-0073-6 PMid:27193105
Garg R, Wollan M, Galic V, Garcia R, Goff BA, Gray HJ, et al. Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma. Gynecol Oncol. 2006;103(3):793-6. https://doi.org/10.1016/j.ygyno.2006.08.043 PMid:17023036
de Souza NC, Brenna SM, Campos F, Syrjanen KJ, Baracat EC, Silva ID. Interleukin-6 polymorphisms and the risk of cervical cancer. Int J Gynecol Cancer. 2006;16(3):1278-82. https://doi.org/10.1111/j.1525-1438.2006.00521.x PMid:16803517
Lu W, He F, Lin Z, Liu S, Tang L, Huang Y, et al. Dysbiosis of the endometrial microbiota and its association with inflammatory cytokines in endometrial cancer. Int J Cancer. 2021;148(7):1708-16. https://doi.org/10.1002/ijc.33428 PMid:33285000
Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: From tumor initiation to metastatic progression. Genes Dev. 2018;32(19-20):1267-84. https://doi.org/10.1101/gad.314617.118 PMid:30275043
Voronov E, Weinstein Y, Benharroch D, Cagnano E, Ofir R, Dobkin M, et al. Antitumor and immunotherapeutic effects of activated invasive T lymphoma cells that display short-term interleukin 1alpha expression. Cancer Res. 1999;59(5):1029-35. PMid:10070959
Hata Y, Nakaoka H, Yoshihara K, Adachi S, Haino K, Yamaguchi M, et al. A nonsynonymous variant of IL1A is associated with endometriosis in Japanese population. J Hum Genet. 2013;58(8):517-20. https://doi.org/10.1038/jhg.2013.32 PMid:23635948
Kolbus A, Walch K, Nagele F, Wenzl R, Unfried G, Huber JC. Interleukin-1 alpha but not interleukin-1 beta gene polymorphism is associated with polycystic ovary syndrome. J Reprod Immunol. 2007;73(2):188-93. https://doi.org/10.1016/j.jri.2006.08.002 PMid:16965825
Liu Y, Sun Y, Wu J, Xiong Z, Du S, Niu F, et al. Polymorphisms in IL-1A are associated with endometrial cancer susceptibility among Chinese Han population: A case-control study. Int J Immunogenet. 2020;47(2):169-74. https://doi.org/10.1111/iji.12463 PMid:31981288
Xia H, Chen Y, Meng J, Liang C. Effect of polymorphism on IL1A to cancer susceptibility: Evidence based on 34,016 subjects. Artif Cells Nanomed Biotechnol. 2019;47(1):3138-52. https://doi.org/10.1080/21691401.2019.1646750 PMid:31359795
Dominici R, Cattaneo M, Malferrari G, Archi D, Mariani C, Grimaldi LM, et al. Cloning and functional analysis of the allelic polymorphism in the transcription regulatory region of interleukin-1 alpha. Immunogenetics. 2002;54(2):82-6. https://doi.org/10.1007/s00251-002-0445-9 PMid:12037600
Cervin SS, González VD, Aguilar-Medina M, Romero-Navarro JG, Romero QJ, Arámbula ME, et al. Genetic polymorphisms of interleukin-1 alpha and the vitamin D receptor in Mexican Mestizo patients with intervertebral disc degeneration. Int J Genomics. 2014;2014:302568. https://doi.org/10.1155/2014/302568 PMid:25506053
Soslow RA, Tornos C, Park KJ, Malpica A, Matias-Guiu X, Oliva E, et al. Endometrial carcinoma diagnosis: Use of FIGO grading and genomic subcategories in clinical practice: Recommendations of the International society of gynecological pathologists. Int J Gynecol Pathol. 2019;38(Iss 1 Suppl 1):S64-74. https://doi.org/10.1097/PGP.0000000000000518 PMid:30550484
Yao L, Chen S, Li W. Fatostatin inhibits the development of endometrial carcinoma in endometrial carcinoma cells and a xenograft model by targeting lipid metabolism. Arch Biochem Biophys. 2020;684:108327. https://doi.org/10.1016/j.abb.2020.108327 PMid:32142890
Zhai K, Yang Y, Gao ZG, Ding J. Interleukin-6-174G>C gene promoter polymorphism and prognosis in patients with cancer. Oncotarget. 2017;8(27):44490-7. https://doi.org/10.18632/oncotarget.17771 PMid:28548958
Benjamin JJ, Koshy T, Kumar KM, Maruthy KN, Padmavathi R. Meta-analysis of association between il-6-174 g/c polymorphism and female infertility related disorders. J Reprod Immunol. 2020;140:103134. https://doi.org/10.1016/j.jri.2020.103134 PMid:32402924
Singh PK, Chandra G, Bogra J, Gupta R, Kumar V, Jain A, et al. Association of interleukin-6 genetic polymorphisms with risk of OSCC in Indian population. Meta Gene. 2015;4:142-51. https://doi.org/10.1016/j.mgene.2015.03.002 PMid:26005639
Ellone S, Watts K, Cane’ S, Palmieri M, Cannon MJ, Burnett A, et al. High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. Gynecol Oncol. 2005;98(1):92-8. https://doi.org/10.1016/j.ygyno.2005.03.016 PMid:15904949
Subramaniam KS, Omar IS, Kwong SC, Mohamed Z, Woo YL, Mat Adenan NA, et al. Cancer-associated fibroblasts promote endometrial cancer growth via activation of interleukin-6/STAT-3/c-Myc pathway. Am J Cancer Res. 2016;6(2):200-13. PMid:27186396
Fisher DT, Appenheimer MM, Evans SS. The two faces of IL-6 in the tumor microenvironment. Semin Immunol. 2014;26(1):38-47. https://doi.org/10.1016/j.smim.2014.01.008 PMid:24602448
Almolakab ZM, El-Nesr KA, Mohamad Hassanin EH, Elkaffas R, Nabil A. Gene polymorphisms of interleukin 6 (−174 G/C) and transforming growth factor β-1(+915 G/C) in ovarian cancer patients. Beni-Suef Univ J Basic Appl Sci. 2022;11:30. https://doi.org/10.1186/s43088-022-00211-5
Wagh P, Kulkarni P, Kerkar S, Tongaonkar H, Chaudhari H, Warke H, et al. Polymorphism of interleukin-6 -174 G/C (rs1800795) and the corresponding interleukin-6 level as a prognostic marker of cervical cancer. Indian J Med Res. 2021;154(2):391-8. https://doi.org/10.4103/ijmr.IJMR_1111_19 PMid:34854425
Hegedus CM, Skibola CF, Bracci P, Holly EA, Smith MT. Screening the human serum proteome for genotype-phenotype associations: An analysis of the IL6–174G>C polymorphism. Proteomics. 2007;7(4):548-57. https://doi.org/10.1002/pmic.200600366 PMid:17309100
Talaat RM, Abdel Aziz AM, El Maadawy EA, Abdel Bary N. CD38 and interleukin 6 gene polymorphism in egyptians with diffuse large B cell lymphoma (DLBCL). Immunol Invest. 2015;44(3):265-78. https://doi.org/10.3109/08820139.2014.989328 PMid:25564959
Sa-Nguanraksa D, Suntiparpluacha M, Kulprom A, Kummalue T, Chuangsuwanich T, Avirutnan P, et al. Association of estrogen receptor alpha and interleukin 6 polymorphisms with lymphovascular invasion, extranodal extension, and lower disease-free survival in thai breast cancer patients. Asian Pac J Cancer Prev. 2016;17(6):2935-40. PMID: 27356714
Ting EY, Yang AC, Tsai SJ. Role of interleukin-6 in depressive disorder. Int J Mol Sci. 2020;21(6):2194. https://doi.org/10.3390/ijms21062194 PMid:32235786
Rana BK, Flatt SW, Health DD, Pakiz B, Quintana EL, Natarajan L, et al. The IL-6 gene promoter SNP and plasma IL-6 in response to diet intervention. Nutrients. 2017;9(6):552. https://doi.org/10.3390/nu9060552 PMid:28555011
Litmanovich A, Khazim K, Cohen I. The role of interleukin-1 in the pathogenesis of cancer and its potential as a therapeutic target in clinical practice. Oncol Ther. 2018;6(2):109-27. https://doi.org/10.1007/s40487-018-0089-z PMid:32700032
Daley-Brown D, Harbuzariu A, Kurian AA, Oprea-Ilies G, Gonzalez-Perez RR. Leptin-induced Notch and IL-1 signaling crosstalk in endometrial adenocarcinoma is associated with invasiveness and chemoresistance. World J Clin Oncol. 2019;10(6):222-33. https://doi.org/10.5306/wjco.v10.i6.222 PMid:31367531
Eser B, Taskin MI, Hismiogullari AA, Aksit H, Bodur AS. The effects of IL-1A and IL-6 genes polymorphisms on gene expressions, hormonal and biochemical parameters in polycystic ovary syndrome. J Obstet Gynaecol. 2017;37(3):358-62. https://doi.org/10.1080/01443615.2016.1256966 PMid:28019133
Braicu EI, Mustea A, Toliat MR, Pirvulescu C, Könsgen D, Sun P, et al. Polymorphism of IL-1α, IL-1β and IL-10 in patients with advanced ovarian cancer: Results of a prospective study with 147 patients. Gynecol Oncol. 2007;104(3):680-5. https://doi.org/10.1016/j.ygyno.2006.10.014 PMid:17141301
Downloads
Published
How to Cite
License
Copyright (c) 2022 Asmaa Ramadan, Reda Hemida, Noha M. Mesbah, Dina Abo-Elmatty, Eman Mehanna (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
